A Nobel laureate co-founded it. Its biggest customer also owns a direct competitor. Its own accountants concluded there is substantial doubt it can continue as a going concern. On July 2, 2026, Scribe Therapeutics filed an S-1 to list on Nasdaq under the ticker SCTX (S-1 cover).

Scribe is a nine-year-old, Alameda-based CRISPR biotech with 89 full-time employees, three drug candidates, one first-in-human trial running in Australia, $49.7 million in the bank, and a burn rate that puts the runway under twelve months without this IPO (S-1). The technology is genuinely differentiated. The finances are a mess. The cap table is a soap opera. This is a 5-minute read on all three.

The origin story

Scribe was founded in June 2017 to commercialize a suite of CRISPR technologies coming out of the Berkeley labs of Jennifer Doudna (the Nobel laureate who co-discovered CRISPR-Cas9) and David Savage (a UC Berkeley molecular biology professor) (S-1). Benjamin Oakes, then finishing a PhD at Berkeley and doing a stint as an Entrepreneurial Fellow at Doudna's Innovative Genomics Institute, took the CEO role. Brett Staahl, a delivery-technology specialist, rounded out the four-person founding team.

The pitch: skip Cas9 (the enzyme every other public CRISPR company is built on) and engineer a smaller, more specific enzyme called CasX. Layer two proprietary systems on top: ELXR for epigenetic silencing without touching DNA, and XE for gene editing. Then, unusually for a CRISPR company, aim the whole thing at prevalent cardiovascular disease rather than rare orphan indications (S-1 Summary).

The company acquired the foundational IP in September 2018 by signing an exclusive license with the UC Regents for the CasX and CasY patent estate (S-1). Over the next seven years, Scribe raised roughly $150 million in equity, plus $180 million more in upfront and milestone payments from strategic partners, plus a $30 million convertible note from Eli Lilly (S-1). Investors include Andreessen Horowitz, Avoro Capital, Menlo Ventures, OrbiMed, Perceptive Advisors, RA Capital, T. Rowe Price, and Wellington Management (S-1).

The people running it

The management team is three deep. That is not a typo.

Benjamin Oakes, 37, co-founder, President, CEO, and the only board director from management (S-1 Management). Colby philosophy-and-neurobiology undergrad; Berkeley PhD in molecular and cellular biology. He founded the company at 28 and has never run anything else.

Svetlana Lucas, Ph.D., 54, Chief Business Officer since June 2019 (S-1 Management). Business development at Tizona Therapeutics (2015 to 2019), external oncology R&D at Amgen after Amgen bought Onyx Pharmaceuticals (where she was Director of Corporate Development), earlier stops at XOMA, Facet, PDL, and McKinsey. Also on the boards of Jasper Therapeutics and aTyr Pharma.

David Parrot, MBA, 57, Chief Financial Officer since December 2021 (S-1 Management). Career life-sciences investment banker: head of West Coast life-sciences banking at Barclays (2019 to 2021), before that the same role at SunTrust Robinson Humphrey, before that BMO, before that Montgomery, before that Piper Jaffray going back to 1998. This is his first operating role at a biotech. Middlebury economics undergrad, Berkeley Haas MBA.

Notice what is missing. There is no Chief Scientific Officer, no Chief Medical Officer, no Chief Operating Officer, no Chief Technology Officer named in the S-1. A clinical-stage biotech running a first-in-human trial with three C-level executives is either a paragon of capital discipline or an operational understaffing waiting to be exposed. Take your pick.

Jennifer Doudna is not on the board and will not be an employee (S-1 Summary). She keeps her UC Berkeley post and remains a paid consultant plus Scientific Advisory Board member. She is also a co-founder of six other CRISPR companies (Azalea, Caribou Biosciences, Editas Medicine, Evercrisp, Intellia Therapeutics, Mammoth Biosciences) and continues to serve on the SABs of Caribou, Evercrisp, Intellia, and Mammoth (S-1 Risk Factors). Investors buying SCTX are not buying access to Doudna.

The rest of the board is three VCs. James Watson (Andreessen Horowitz's Bio + Health team, joined July 2025), Behzad Aghazadeh (Managing Partner at Avoro Capital, joined March 2021), and Carl Gordon (Managing Partner at OrbiMed, joined March 2021) (S-1 Management). Every non-employee director represents a fund on the cap table.

By the numbers

  • 2024 collaboration revenue: $27.4 million. 2025: $51.2 million (up 87% year over year) (S-1 Summary Financial Data). Zero product revenue, ever.
  • Q1 2026 revenue: $2.2 million, down from $17.1 million in Q1 2025 (S-1). Not a business problem, an accounting problem: the $15.6 million of Sanofi 2022 deferred revenue amortized out at the end of 2025. Expect flat-to-ugly reported revenue for the rest of 2026.
  • R&D spend in 2025: $60.8 million. G&A: $16.4 million (S-1). Ninety-eight percent of the $77.2 million operating cost base is R&D, which is what you want to see at a clinical-stage biotech.
  • 2024 net loss: $47.8 million. 2025: $21.8 million (softened by collaboration revenue). Q1 2026: $17.4 million, or roughly $70 million annualized (S-1).
  • Cash, equivalents, and investments as of March 31, 2026: $49.7 million (S-1). Against a $17 million quarterly burn, that is under a year of runway.
  • Accumulated deficit: $175.1 million. Total stockholders' equity: negative $158.7 million (S-1 Capitalization).
  • Convertible note held by Lilly: $40.5 million carrying value on a $30 million principal amount at 8% interest, maturing May 2026 (S-1). It automatically converts into common stock at IPO at a 5% to 15% discount to the offering price.
  • Going concern: "Our management and our independent registered public accounting firm have concluded that there is substantial doubt as to our ability to continue as a going concern" (S-1 Risk Factors). That is the actual language.

The financial story is straightforward. Cash runs out inside a year. The IPO is not a nice-to-have.

What could break

Sanofi and Lilly are 100% of revenue. In 2025, Lilly's Prevail Therapeutics subsidiary drove $35.1 million of the $51.2 million collaboration line, the older Sanofi 2022 deal drove $15.6 million (via deferred-revenue amortization that has now ended), and the newer Sanofi 2023 sickle-cell deal drove $0.5 million (S-1 Notes to Financial Statements). If either partner walks, revenue collapses to near zero until STX-1150 is approved, which is many years away if it happens at all.

Lilly is partner, largest customer, creditor, more than 5% shareholder, and, through Verve Therapeutics, direct competitor (S-1 Business). Prevail, a Lilly subsidiary, wrote Scribe the $45 million Prevail License Agreement in May 2023 (up to $150 million in R&D milestones plus $1.4 billion in commercial milestones plus royalties) (S-1). Lilly also holds a $30 million convertible note and shows up in the Principal Stockholders table as a more-than-5% owner (S-1 Principal Stockholders). And Verve Therapeutics, also a Lilly subsidiary, is developing a competing PCSK9 gene editing therapy going head-to-head with Scribe's lead candidate. That is not conflicted litigation, but it is deeply conflicted commercial incentive.

The Berkeley license is the whole company. Scribe's CasX and CasY IP comes from the Regents of the University of California under an exclusive license that requires Scribe to hit specific development milestones by specific dates (S-1). Miss those, or breach any other material term, and the Regents can terminate. The S-1 language: "If the license is terminated, we may be unable to develop, manufacture, sell, or use our CRISPR-based technologies and products that are covered by the patents licensed under the UCB Exclusive License Agreement" (S-1 Risk Factors). That is not a garden-variety risk factor. That is the company.

Novel modality risk. ELXR is epigenetic silencing: it deposits DNA methylation and repressive histone marks at a target locus without cutting DNA. That mechanism has never been clinically validated for a durable human therapy (S-1 Risk Factors). The preclinical package looks great (in non-human primates, a single dose of a prototype STX-1150 produced greater than 50% LDL-C reduction sustained for two years at the lowest tested dose of 0.75 mg/kg) (S-1). "Beautiful in NHPs" is a graveyard sentence in biotech. Human data reads out in the first half of 2027.

Doudna's conflicts. Beyond the six co-founded companies and four active SAB roles, Scribe's contractual mitigations amount to confidentiality obligations, a certification not to breach, a notification requirement, and Scribe's right to modify her consulting agreement in writing (S-1 Risk Factors). There is no separate conflict-of-interest policy. If she picks up the phone at Intellia and mentions something she heard at Scribe, the recovery mechanism is a Fenwick lawsuit.

The offering

This is a preliminary S-1 filed on July 2, 2026, with all pricing details left blank. Share count, price range, and post-money valuation are placeholders in the document (S-1 cover). Expect a priced S-1/A with a roadshow in the following weeks.

Underwriters: Leerink Partners on the far left, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities (S-1 cover). Leerink is the healthcare specialist and typically leads deals like this. Goldman and Wells Fargo are bulge-bracket. Guggenheim is a solid middle-market shop. This is a syndicate you can take seriously, not a two-shop banking effort that would flag a weak deal.

Use of proceeds is unquantified but directional: continue STX-1150 through clinical trials, push STX-1200 and STX-1400 through preclinical toward a Phase 1 initiation in 2027 or 2028, keep developing ELXR and XE, general corporate purposes (S-1 Use of Proceeds). Management concedes explicitly that IPO proceeds plus current cash will not get them through regulatory approval on any program. Another raise is coming.

Existing more-than-5% owners (percentages blank in the initial filing): entities affiliated with Andreessen Horowitz, entities affiliated with Avoro Life Sciences, Eli Lilly and Company, Jennifer A. Doudna, and Brett T. Staahl (S-1 Principal Stockholders).

The take

Scribe is engineering-quality science standing on a financial cliff. The bull case is straightforward: ELXR is a genuinely novel CRISPR modality, the non-human primate durability data on STX-1150 is striking, and the PCSK9 category is a real $5 billion-plus market that current therapies address poorly because patients stop taking them. If STX-1150 posts clean, durable LDL-C reduction in the Australian Phase 1 by mid-2027, this stock is a re-rating story.

The bear case is that the going-concern flag is not rhetorical, revenue is entirely captive to two pharma partners, the entire foundational IP sits inside a terminable license from a university, and Scribe's lead program competes head-on with a Lilly subsidiary while Lilly is Scribe's largest customer, a shareholder, and its largest creditor. Any of those single-thread risks is enough to break the equity.

For the bull case to work, three things must go right: STX-1150 needs to show statistically clean LDL-C data in the Australian trial in 1H 2027, Scribe needs to close a substantial follow-on round in the next 12 months on non-punitive terms, and Lilly needs to keep playing partner while Verve competes on the same target. Two of those failing, and SCTX is a low-single-digits stock. All three going right, and this is one of the more interesting cardiometabolic bets of the year.

Sources

Not financial advice.